Mirati Therapeutics, Inc. (NASDAQ:MRTX) Q2 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Mirati Therapeutics Second Quarter 2023 Earnings Call. My name is Justin, and I will be the operator for today's call.
Mirati Therapeutics Inc. (MRTX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 6,666,666 | $290,399,971 | +20% | 4.52% |
| 2. | EcoR1 Capital Oleg Nodelman | 5,748,399 | $250,400,260 | 8.44% | |
| 3. | OrbiMed Advisors Samuel Isaly | 1,959,050 | $85,336,218 | +115% | 1.81% |
| 4. | Baker Bros. Advisors Julian Baker And Felix Baker | 1,409,784 | $61,410,191 | 0.35% | |
| 5. | Armistice Capital Steven Boyd | 1,364,098 | $59,420,109 | -66% | 0.91% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $27.80 | 1,201,440 | 3,201,440 | 2023-08-11 | Filing | ||
| $27.80 | 57,533 | 287,866 | 2023-08-11 | Filing | ||
| $27.80 | 1,201,440 | 3,201,440 | 2023-08-11 | Filing | ||
| $27.80 | 57,533 | 287,866 | 2023-08-11 | Filing | ||
| $27.80 | 10,791 | Director | 10,791 | 2023-08-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $35.63 | 2,388 | Officer | 144,032 | 2023-09-08 | Filing | |
| $37.06 | 4,647 | Officer | 80,015 | 2023-06-02 | Filing | |
| $45.29 | 619 | Officer | 124,123 | 2023-05-24 | Filing | |
| $44.66 | 2,546 | 0 | 2023-01-18 | Filing | ||
| $42.38 | 3,179 | 61,792 | 2023-01-17 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,768,514 | $294,836,470 | 6.22% | |
| 2. | 5,699,632 | $248,275,969 | 0% | |
| 3. | 3,544,311 | $154,390,188 | 0% | |
| 4. | 3,319,922 | $144,615,802 | 0.02% | |
| 5. | 3,201,440 | $139,454,726 | 7.42% |
News See All
Mirati Therapeutics, Inc. (NASDAQ:MRTX) Q1 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Mirati Therapeutics First Quarter 2023 Earnings Call. My name is Justin, and I will be the operator for today’s call.
Mirati Therapeutics, Inc. (NASDAQ:MRTX) Q4 2022 Earnings Call Transcript
Operator: Good afternoon and welcome to the Mirati Therapeutics Fourth Quarter 2022 Earnings Call. My name is Cynthia and I'll be the operator for today's call.
Mirati Therapeutics, Inc. (NASDAQ:MRTX) Q3 2022 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Mirati Therapeutics Third Quarter 2022 Earnings Call. My name is Jenny, and I will be the operator for today's call.
5 Best Pharmaceutical Stocks to Buy According to Steven Boyd's Armistice Capital
In this article, we will take a look at some important pharma stock picks of Steven Boyd's Armistice Capital.
3 Stocks to Buy According to Devesh Gandhi’s SilverArc Capital
In this article, we will discuss the top 3 stocks to buy according to Devesh Gandhi’s SilverArc Capital.
Top 10 Stocks Billionaire Mets Owner Steve Cohen Just Added to His Portfolio
In this article we present the list of top 10 stocks billionaire Mets owner Steve Cohen just added to his portfolio.
Is Mirati Therapeutics (MRTX) A Smart Long-Term Buy?
Baron Funds, an asset management firm, published its “Baron Opportunity Fund” fourth quarter 2021 investor letter – a copy of which can be downloaded here.
Did Hedge Funds Get Mirati Therapeutics, Inc. (MRTX) Right?
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.
Billionaire Hedge Funds
